Roivant Sciences (NASDAQ:ROIV) Announces Earnings Results

Roivant Sciences (NASDAQ:ROIV) posted its quarterly earnings data on Monday. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04, Zacks reports. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $10.79 on Tuesday. Roivant Sciences has a 1-year low of $9.76 and a 1-year high of $13.06. The company has a 50-day moving average of $11.51 and a 200 day moving average of $11.60. The firm has a market cap of $7.85 billion, a PE ratio of 1.91 and a beta of 1.25.

Insider Buying and Selling at Roivant Sciences

In other news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the stock in a transaction dated Monday, January 13th. The shares were acquired at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CIO Mayukh Sukhatme sold 412,584 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the transaction, the executive now owns 18,836,547 shares of the company’s stock, valued at approximately $226,980,391.35. This trade represents a 2.14 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,942,629 shares of company stock valued at $23,034,486. Company insiders own 7.90% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.